Výsledky vyhledávání - "Vinod Bambure"

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine

Autor: Sumita Roy-Ghanta, Carl-Erik Flodmark, Sven Arne Silfverdal, Timo Vesikari, Adrian Caplanusi, Tiina Korhonen, Ilse Dieussaert, Ann Lindstrand, David W. Vaughn, Vinod Bambure, Jan Hendrik Richardus, Johan Berglund

Publikováno v: Pediatric Infectious Disease Journal, 34(7), 774-782. Lippincott Williams & Wilkins

Background: During the influenza pandemic 2009-2010, an AS03-adjuvanted A(H1N1) pdm09 vaccine was used extensively in children 6 months of age and older, and during the 2010-2011 influenza season, the A(H1N1) pdm09 strain was included in the seasonal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f52c3c8463ef8cf84e783bfdef211b81
https://doi.org/10.1097/inf.0000000000000709

Zobrazit plný text záznamu

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

Autor: Juan C. Tejedor, Philippe Moris, Ilse Dieussaert, Karl Walravens, Jose Manuel Merino, Felix Omeñaca, Alfonso Carmona, Paul Gillard, José Garcia-Sicilia, Javier Arístegui, Vinod Bambure, Pilar García-Corbeira, Adrian Caplanusi

Publikováno v: Human Vaccines & Immunotherapeutics
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

In children, 2 AS03-adjuvanted A(H1N1)pdm09 vaccine doses given 21 days apart were previously shown to induce a high humoral immune response and to have an acceptable safety profile up to 42 days following the first vaccination. Here, we analyzed the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5b0232bed10e97f170e4161ae7e767
http://europepmc.org/articles/PMC4635840

Zobrazit plný text záznamu

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

Autor: Wolfgang Jilg, Veerachai Watanveerade, Tino F. Schwarz, Ping Li, May Montellano, Gérard Zalcman, Serge Fitoussi, David W. Vaughn, Angkool Kerdpanich, Odile Launay, Xavier Duval, Vinod Bambure, Paul Gillard, Adrian Caplanusi, Anuradha Madan, Jürgen J. Wenzel

Publikováno v: BMC Infectious Diseases
BMC Infectious Diseases, BioMed Central, 2013, 13 (1), pp.435. ⟨10.1186/1471-2334-13-435⟩

Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/Californ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8267ecf34b2938ffe505d0a3ad5bf45e
https://www.hal.inserm.fr/inserm-00868824

Zobrazit plný text záznamu

Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older

Autor: Paul Gillard, Vinod Bambure, Emmanuel Hanon, Philippe Moris, Froukje Kafeja, Pierre Van Damme, François Roman

Publikováno v: Human vaccines & immunotherapeutics

This manuscript presents data on the persistence of Hemagglutination Inhibition (HI) immune response against the A/California/7/2009 strain, six and 12 mo after adults received one dose (n = 138) or two doses (n = 102; 21 d apart) of a 3.75 mu g Hema

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f896128aaee2b495fee5592a053be6
https://pubmed.ncbi.nlm.nih.gov/23571166

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání